| P/E (FY) | — | Sales (TTM) | $32.7M |
| Earnings (TTM) | -$54.6M | ROE | — |
| Net Margin | −157.40% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 111.62% |
| Market Cap | $231.1M | Trading Days | 872 |
| 52W High | 5.42 |
| 52W Low | 2.20 |
| % Off High | −28.83% |
| YTD | −6.99% | 1Y | 13.53% |
| 3Y | −27.99% | Since incept. (ann.) | −26.80% |
Partnership Revenue 98% · Product 2%
| Ann. Volatility (1Y) | 72.13% | Ann. Volatility (3Y) | 95.38% |
| Sharpe (1Y) | 0.54 | Sharpe (3Y) | 0.30 |
| Max Drawdown (1Y) | −34.77% | Max Drawdown (3Y) | −78.18% |
| Beta (3Y, vs SPY) | 1.53 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| UTMD | UTAH MEDICAL PRODUCTS INC | $225.9M | 20.4 |
| EMBC | Embecta Corp. | $213.0M | 2.2 |
| PROF | Profound Medical Corp. | $263.4M | 5.1 |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | $264.7M | — |
| ANIK | Anika Therapeutics, Inc. | $201.6M | — |
| TLSI | TriSalus Life Sciences, Inc. | $265.9M | — |
| INFU | InfuSystem Holdings, Inc | $200.2M | 32.0 |
| OSUR | ORASURE TECHNOLOGIES INC | $276.8M | — |
| LUCD | Lucid Diagnostics Inc. | $185.7M | — |
| SGHT | Sight Sciences, Inc. | $288.4M | — |
| KRMD | KORU Medical Systems, Inc. | $184.2M | — |
| PSTV | PLUS THERAPEUTICS, INC. | $292.5M | — |
